| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Workers are cheating on drug tests at the highest rate in more than 30 years, according to one of the U.S.’s largest drug-testing labs. The increase in tampered tests came from samples collected in 2023. About 31,000 drug screens out of 5.5 million showed signs of cheating, according to Quest Diagnostics. “Some American workers are going to great lengths to attempt to subvert the drug-testing process,” said Dr. Suhash Harwani, senior director of science for workforce health solutions at Quest. The percentage of urine samples that came back positive for drugs among the U.S. workforce remained steady at a two-decade high for the third year in a row. But the substantial rise of tampering, as well as the patchwork of new marijuana laws across the U.S., have intensified challenges for employers seeking to keep drugs out of the workplace.
Quest Diagnostics is building out its artificial intelligence-powered cancer pathology offerings through a multi-layered deal with PathAI—acquiring some assets, licensing out others. The testing giant will be buying out PathAI’s Memphis, Tennessee-based diagnostics laboratory, with plans to turn it into its own AI and digital R&D solutions center to help support its current AmeriPath and Dermpath Diagnostics pathology businesses.
Quest Diagnostics suggested Tuesday that laboratory industry staffing shortages could redound to its benefit as hospital labs are forced to either scale back or sell off their lab operations. On a conference call following the release of the company's Q1 2024 earnings results, Quest Chairman, President, and CEO Jim Davis observed that the company has seen particular strength in hospital reference testing as that portion of its business continued to grow at a faster rate than it had prior to the COVID-19 pandemic. He said that this trend was driven in part by the lab business's much discussed workforce crunch, noting that hospitals "face persistent challenges with staffing certain roles in specialized fields like histology, microbiology, and cytotechnology."
A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer’s disease (AD) is likely not the cause of patients’ mild cognitive impairment, finds a new study published in Frontiers in Neurology by researchers from Quest Diagnostics, the University of Florida and Mount Sinai Medical Center in Miami Beach.
Precision medicine in rheumatoid arthritis expanded in a small but key measure late last year, when Quest Diagnostics and Scipher Medicine announced a partnership to provide RNA extraction and sequencing services for the latter’s PrismRA test.